Wirkstoffe & Arzneimittelsicherheit

Wechselwirkungen · Kaletra

Kaletra 200 mg/50 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 53–54

HOS-109013 · Präparat HOS-093083

53  benefit/risk to patient justifies the use of voriconazole. Anti-gout agents Colchicine single dose Colchicine: Concomitant administration of AUC: ↑ 3-fold Kaletra with colchicine in patients (Ritonavir 200 mg Cmax: ↑ 1.8-fold with renal and/or hepatic impairment twice-daily) Due to P-gp and/or CYP3A4 is contraindicated due to a potential inhibition by ritonavir. increase of colchicine-related serious and/or life-threatening reactions such as neuromuscular toxicity (including rhabdomyolysis) (see sections 4.3 and 4.4). A reduction in colchicine dosage or an interruption of colchicine treatment is recommended in patients with normal renal or hepatic function if treatment with Kaletra is required. Refer to colchicine prescribing information. Antihistamines Astemizole Serum concentrations may be Concomitant administration of Terfenadine increased due to CYP3A Kaletra and astemizole and inhibition by lopinavir/ritonavir. terfenadine is contraindicated as it may increase the risk of serious arrhythmias from these agents (see section 4.3). Anti-infectives Fusidic acid Fusidic acid: Concomitant administration of Concentrations may be increased Kaletra with fusidic acid is contra- due to CYP3A inhibition by indicated in dermatological lopinavir/ritonavir. indications due to the increased risk of adverse events related to fusidic acid, notably rhabdomyolysis (see section 4.3). When used for osteo- articular infections, where the co- administration is unavoidable, close clinical monitoring for muscular adverse events is strongly recommended (see section 4.4). Antimycobacterials Bedaquiline Bedaquiline: Due to the risk of bedaquiline related (single dose) AUC: ↑ 22% adverse events, the combination of Cmax: ↔ bedaquiline and Kaletra should be (Lopinavir/ritonavir avoided. If the benefit outweighs the 400/100 mg BID, A more pronounced effect on risk, co-administration of bedaquiline multiple dose) bedaquiline plasma exposures with Kaletra must be done with may be observed during caution. More frequent prolonged co-administration with electrocardiogram monitoring and lopinavir/ritonavir. monitoring of transaminases is recommended (see section 4.4 and CYP3A4 inhibition likely due to refer to the bedaquiline SmPC). lopinavir/ritonavir.

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): fusidic acid (HOS-086146) bedaquiline (HOS-086268) voriconazole (HOS-084524) colchicine (HOS-086147) astemizole (HOS-085608) terfenadine (HOS-085607)